Amphastar Pharmaceuticals, Inc. (AMPH) stock
AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3033% below fair value
$28.87+0.27 (+0.94%)
Close on Nov 12, 2026Market cap $1.23BP/E 13.1Yield –
Amphastar Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Amphastar Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $92.29M, up 14.4% year over year. For fiscal 2025 it was $85.84M, up 16.1% from the year before. Over ten years it grew 8.7% a year on average. The highest annual figure on record is $85.84M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.84M | +16.1% |
| FY2024 | Dec 31, 2024 | $73.91M | +0.2% |
| FY2023 | Dec 31, 2023 | $73.74M | -1.4% |
| FY2022 | Dec 31, 2022 | $74.77M | +22.7% |
| FY2021 | Dec 31, 2021 | $60.93M | -9.4% |
| FY2020 | Dec 31, 2020 | $67.23M | -2.4% |
| FY2019 | Dec 31, 2019 | $68.85M | +19.6% |
| FY2018 | Dec 31, 2018 | $57.56M | +32.3% |
| FY2017 | Dec 31, 2017 | $43.50M | +4.8% |
| FY2016 | Dec 31, 2016 | $41.52M | +11.4% |
| FY2015 | Dec 31, 2015 | $37.27M | +29.1% |
| FY2014 | Dec 31, 2014 | $28.87M | -12.6% |
| FY2013 | Dec 31, 2013 | $33.02M | +6.0% |
| FY2012 | Dec 31, 2012 | $31.16M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $20.08M | -10.2% |
| Q2 FY2026 | Jun 30, 2026 | $22.16M | +10.4% |
| Q1 FY2026 | Mar 31, 2026 | $26.74M | +33.0% |
| Q4 FY2025 | Dec 31, 2025 | $23.31M | +28.5% |
| Q3 FY2025 | Sep 30, 2025 | $22.35M | +6.1% |
| Q2 FY2025 | Jun 30, 2025 | $20.08M | +13.8% |
| Q1 FY2025 | Mar 31, 2025 | $20.10M | +17.9% |
| Q4 FY2024 | Dec 31, 2024 | $18.14M | -11.2% |
| Q3 FY2024 | Sep 30, 2024 | $21.08M | +26.5% |
| Q2 FY2024 | Jun 30, 2024 | $17.65M | +4.8% |
| Q1 FY2024 | Mar 31, 2024 | $17.04M | -14.0% |
| Q4 FY2023 | Dec 31, 2023 | $20.42M | +18.5% |
| Q3 FY2023 | Sep 30, 2023 | $16.66M | -10.0% |
| Q2 FY2023 | Jun 30, 2023 | $16.84M | -26.1% |
| Q1 FY2023 | Mar 31, 2023 | $19.82M | +22.1% |
| Q4 FY2022 | Dec 31, 2022 | $17.24M | -0.3% |
| Q3 FY2022 | Sep 30, 2022 | $18.51M | +72.1% |
| Q2 FY2022 | Jun 30, 2022 | $22.80M | +25.8% |
| Q1 FY2022 | Mar 31, 2022 | $16.22M | +9.9% |
| Q4 FY2021 | Dec 31, 2021 | $17.29M | -4.7% |
| Q3 FY2021 | Sep 30, 2021 | $10.76M | -39.0% |
| Q2 FY2021 | Jun 30, 2021 | $18.12M | +12.2% |
| Q1 FY2021 | Mar 31, 2021 | $14.77M | -3.5% |
| Q4 FY2020 | Dec 31, 2020 | $18.13M | -7.7% |
| Q3 FY2020 | Sep 30, 2020 | $17.64M | -5.2% |
| Q2 FY2020 | Jun 30, 2020 | $16.15M | +1.0% |
| Q1 FY2020 | Mar 31, 2020 | $15.30M | +4.8% |
| Q4 FY2019 | Dec 31, 2019 | $19.64M | +17.4% |
| Q3 FY2019 | Sep 30, 2019 | $18.61M | +64.1% |
| Q2 FY2019 | Jun 30, 2019 | $16.00M | +3.5% |
| Q1 FY2019 | Mar 31, 2019 | $14.61M | +4.1% |
| Q4 FY2018 | Dec 31, 2018 | $16.73M | +47.0% |
| Q3 FY2018 | Sep 30, 2018 | $11.34M | +12.6% |
| Q2 FY2018 | Jun 30, 2018 | $15.46M | +44.1% |
| Q1 FY2018 | Mar 31, 2018 | $14.03M | +24.7% |
| Q4 FY2017 | Dec 31, 2017 | $11.39M | -9.6% |
| Q3 FY2017 | Sep 30, 2017 | $10.08M | – |
| Q2 FY2017 | Jun 30, 2017 | $10.73M | – |
| Q1 FY2017 | Mar 31, 2017 | $11.25M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.60M | – |
See a number that looks wrong?